{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:52:36Z","timestamp":1787161956720,"version":"build-2736575974"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,9,15]]},"DOI":"10.2169\/internalmedicine.3259-23","type":"journal-article","created":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T17:11:59Z","timestamp":1707671519000},"page":"2491-2497","source":"Crossref","is-referenced-by-count":7,"title":["Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor\/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease"],"prefix":"10.2169","volume":"63","author":[{"given":"Toru","family":"Ishikawa","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Saiseikai Niigata Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanako","family":"Terai","sequence":"additional","affiliation":[{"name":"Department of Radiographer, Saiseikai Niigata Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saiseikai Niigata Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Jimbo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saiseikai Niigata Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saiseikai Niigata Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saiseikai Niigata Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Iwanaga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saiseikai Niigata Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoe","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saiseikai Niigata Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saiseikai Niigata Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terasu","family":"Honma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saiseikai Niigata Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 10: 284-296, 2022.","DOI":"10.1016\/S2213-8587(22)00003-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. J Gastroenterol 56: 951-963, 2021.","DOI":"10.1007\/s00535-021-01796-x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Takahashi H, Kessoku T, Kawanaka M, et al. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun 6: 120-132, 2022.","DOI":"10.1002\/hep4.1696"},{"key":"4","unstructured":"4. Ishikawa T, Imai M, Endo S, et al. Clinical efficacy of an SGLT2 inhibitor in type 2 diabetes complicated by nonalcoholic fatty liver disease and changes in body composition. Gut Gastroenterol 3: 1-6, 2020."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Newsome PN, Buchholtz K, Cusi K, et al; the NN9931-4296 Investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384: 1113-1124, 2021.","DOI":"10.1056\/NEJMoa2028395"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Jastreboff AM, Aronne LJ, Ahmad NN, et al; the SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387: 205-216, 2022.","DOI":"10.1056\/NEJMoa2206038"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Abe M, Miyake T, Kuno A, et al. Association between <i>Wisteria floribunda<\/i> agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 50: 776-784, 2015.","DOI":"10.1007\/s00535-014-1007-2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sumida Y, Yoneda M, Hyogo H, et al; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 12: 2, 2012.","DOI":"10.1186\/1471-230X-12-2"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45: 846-854, 2007.","DOI":"10.1002\/hep.21496"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33: 550-558, 2015.","DOI":"10.1200\/JCO.2014.57.9151"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 85: 115-122, 1998.","DOI":"10.1152\/jappl.1998.85.1.115"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31: 1539-1547, 2013.","DOI":"10.1200\/JCO.2012.45.2722"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Goodpaster BH, Carlson CL, Visser M, et al. Attenuation of skeletal muscle and strength in the elderly: the Health ABC Study. J Appl Physiol 90: 2157-2165, 2001.","DOI":"10.1152\/jappl.2001.90.6.2157"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care 41: 1801-1808, 2018.","DOI":"10.2337\/dc18-0165"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sumida Y, Murotani K, Saito M, et al. Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective, single-arm trial (LEAD trial). Hepatol Res 49: 64-71, 2019.","DOI":"10.1111\/hepr.13236"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Eguchi Y, Kitajima Y, Hyogo H, et al; Japan Study Group for NAFLD (JSG-NAFLD). Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res 45: 269-278, 2015.","DOI":"10.1111\/hepr.12351"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 64: 399-408, 2016.","DOI":"10.1016\/j.jhep.2015.08.038"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ohki T, Isogawa A, Iwamoto M, et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. Sci World J 2012: 496453, 2012.","DOI":"10.1100\/2012\/496453"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 79: 1542-1556, 2023.","DOI":"10.1097\/HEP.0000000000000696"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/18\/63_3259-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T23:28:52Z","timestamp":1726874932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/18\/63_3259-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,15]]},"references-count":20,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3259-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,15]]},"article-number":"3259-23"}}